A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

Current treatment for gastroesophageal reflux disease (GERD) confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric-acid suppression. Clinical data on AH234844 demonstrates a rapid onset of action, high potency, and prolonged duration of effect. The present study endeavors, in part, to compare lavoltidine to two GERD drugs, NEXIUM and ranitidine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Esomeprazole; Loxtidine; Ranitidine; Ranitidine bismuth citrate

Criteria

Inclusion criteria:

• Subject must have a Body Mass Index (BMI) from 19-30 kg/m2

• Subject does not present with abnormal clinical lab findings

• Subject is able to tolerate a nasogastric pH electrode.

Exclusion criteria:

• Subject is Helicobacter-positive on a C13 urea breath test

• Subject has a baseline median 24-hour gastric pH>3

• For Part B of the study, subjects are CYP 2C19 poor metabolizers.